ClinicalTrials.gg

Program

deulumateperone

Also written as “ITI-1284”, “ITI-1284 10 mg” and “ITI-1284 20 mg”.

Its studies are mostly in Generalized Anxiety Disorder · Dementia · Psychotic Disorders, led by Johnson & Johnson.

Furthest: phase 3, since Sep 2, 20268 company-led studies, 6 open or runningNext primary completion: Mar 16, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson86 open or runningphase 3since Sep 2, 2026Mar 1, 2024Mar 16, 2027phase 2 · NCT06480383
  • Named in Johnson & Johnson’s own pipeline as ITI-1284, phase 2, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06299410 · 58 enrolled · United States
  2. Jun 24, 2024Phase 2 study in Generalized Anxiety DisorderNCT06480383 · 705 planned · United States, Bulgaria, Czechia and more
  3. Aug 2, 2024Phase 2 study in Psychotic DisordersNCT06540833 · 370 planned · United States, Bulgaria, Croatia and more
  4. Oct 18, 2024Phase 2 study in Agitation Associated With Alzheimer's DementiaNCT06651567 · 320 planned · United States, Bulgaria, Croatia and more
  5. Nov 20, 2024Phase 2 study in Generalized Anxiety DisorderNCT06701903 · 570 planned · United States, Bulgaria, Poland and more
  6. Jan 15, 2025Phase 1 study in Healthy VolunteersNCT06786286 · 8 enrolled · United Kingdom
  7. Sep 2, 20262 phase 3 studies in Generalized Anxiety DisorderPhase 3 reachedNCT07807865, NCT07856420

Ahead

  1. Mar 16, 2027Primary completion: phase 2 study in Generalized Anxiety DisorderNCT06480383
  2. Oct 14, 2027Primary completion: phase 2 study in Generalized Anxiety DisorderNCT06701903
  3. Dec 28, 2027Primary completion: phase 2 study in Agitation Associated With Alzheimer's DementiaNCT06651567
  4. Sep 30, 2028Primary completion: phase 2 study in Psychotic DisordersNCT06540833

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07856420Generalized Anxiety Disorder · United States3RecruitingSep 20, 2030705
NCT07807865Generalized Anxiety Disorder · United States3RecruitingFeb 18, 2030900
NCT06786286Healthy Volunteers · United Kingdom1CompletedMar 26, 20258
NCT06701903Generalized Anxiety Disorder · United States, Bulgaria, Poland and more2RecruitingOct 14, 2027570
NCT06651567Agitation Associated With Alzheimer's Dementia · United States, Bulgaria, Croatia and more2RecruitingDec 28, 2027320
NCT06540833Psychotic Disorders · United States, Bulgaria, Croatia and more2RecruitingSep 30, 2028370
NCT06480383Generalized Anxiety Disorder · United States, Bulgaria, Czechia and more2RecruitingMar 16, 2027705
NCT06299410Healthy Volunteers · United States1CompletedAug 18, 202658

How it is read

Names in the registry

  • “ITI-1284”, 3 entries
  • “ITI-1284 10 mg”, 3 entries
  • “ITI-1284 20 mg”, 3 entries
  • “JNJ-99245354”, 1 entry
  • “[14C]-ITI-1284”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.